================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 6, 2006 Date of Report (Date of earliest event reported) ORAGENICS, INC. (Exact name of registrant as specified in its charter) Florida 000-50614 59-3410522 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 13200 Progress Boulevard Alachua, Florida 32615 (Address of principal executive offices including zip code) (386) 418-4018 Registrant's telephone number, including area code - -------------------------------------------------------------------------------- None - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report.) - -------------------------------------------------------------------------------- ================================================================================ Item 1.01 ENTRY INTO MATERIAL DEFINITIVE AGREEMENTS Oragenics, Inc. (the "Company") closed on the $600,000 private placement of Company common stock and warrants pursuant to the Securities Purchase Agreement previously described in its Form 8-K filing on January 11, 2006. The Company issued 1,500,000 shares of its common stock at $0.40 per share and 1,500,000 warrants to purchase common stock at an exercise price of $0.60 per share to accredited investors who were also existing shareholders of the Company. The warrants are exercisable for two years and are callable by the Company if its common stock trades at or above $1.60 per share for a 30 consecutive day period. Pursuant to the terms of a Registration Rights Agreement dated January 6, 2006, the Company is obligated to file a registration statement with the Securities and Exchange Commission within forty five days covering the resale of shares of common stock purchased by the private investors and the shares of common stock issuable upon exercise of the warrants. The private placement offering and sale of common stock and warrants was made in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933. The proceeds from the private offering will be used for general corporate purposes. Also, the Company voluntarily repaid all remaining principal and interest on its bank loan. A copy of the March 7, 2006 press release announcing the closing of the private placement is attached to this report as Exhibit 99.1 and is incorporated herein by reference. Item 3.02 UNREGISTERED SALES OF EQUITY SECURITIES. The information in Item 1.01 of this report is incorporated herein by reference. Item 9.01 FINANCIAL INFORMATION AND EXHIBITS (c) Exhibits. - -------------------------------------------------------------------------------- Number Description - ------ ----------- - -------------------------------------------------------------------------------- 4.1 Securities Purchase Agreement dated January 6, 2006 - -------------------------------------------------------------------------------- 4.2 Registration Rights Agreement dated January 6, 2006 - -------------------------------------------------------------------------------- 4.3 Specimen Warrant Certificate - -------------------------------------------------------------------------------- 99.1 Press Release dated March 7, 2006 - -------------------------------------------------------------------------------- SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 10th day of March, 2006. ORAGENICS, INC. (Registrant) BY: /s/ Robert T. Zahradnik Robert T. Zahradnik President and Chief Executive Officer